Carmustine

Home
About
Help
History (1)
- Carmustine
- See All Pages

"Carmustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)

Descriptor ID	D002330
MeSH Number(s)	D02.654.692.247 D02.948.594.247
Concept/Terms	Carmustine Carmustine BCNU N,N'-Bis(2-Chloroethyl)-N-Nitrosourea 1,3-Bis(2-Chloroethyl)-1-Nitrosourea FIVB BiCNU BiCNU Nitrumon Nitrumon

Below are MeSH descriptors whose meaning is more general than "Carmustine".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Nitroso Compounds [D02.654]
Nitrosourea Compounds [D02.654.692]
Carmustine [D02.654.692.247]
Urea [D02.948]
Nitrosourea Compounds [D02.948.594]
Carmustine [D02.948.594.247]

Below are MeSH descriptors whose meaning is related to "Carmustine".

Below are MeSH descriptors whose meaning is more specific than "Carmustine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carmustine" by people in this website by year, and whether "Carmustine" was a major or minor topic of these publications.

Bar chart showing 5 publications over 4 distinct years, with a maximum of 2 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	1	2
2009	0	1	1
2010	0	1	1
2020	0	1	1

Below are the most recent publications written about "Carmustine" by people in Profiles.

Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.

View in: PubMed
Thamilselvan V, Menon M, Stein GS, Valeriote F, Thamilselvan S. Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. J Cell Biochem. 2017 12; 118(12):4331-4340.

View in: PubMed
Mihaliak AM, Gilbert CA, Li L, Daou MC, Moser RP, Reeves A, Cochran BH, Ross AH. Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett. 2010 Oct 28; 296(2):168-77.

View in: PubMed
Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13.

View in: PubMed
Kirsch JD, Yi AK, Spitz DR, Krieg AM. Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. Antisense Nucleic Acid Drug Dev. 2002 Oct; 12(5):327-40.

View in: PubMed
Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002 Aug 01; 62(15):4307-15.

View in: PubMed
Recht L, Fram RJ, Strauss G, Fitzgerald TJ, Liepman M, Lew R, Kadish S, Sherman D, Wilson J, Greenberger J, et al. Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial. Am J Clin Oncol. 1990 Apr; 13(2):125-31.

View in: PubMed
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25.

View in: PubMed
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol. 1986 May; 4(5):646-54.

View in: PubMed
Abelson HT, Karlan D, Penman S. A comparison of the effects of alkylating agents 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and nitrogen mustard on nuclear RNA synthesis and processing. Biochim Biophys Acta. 1974 May 31; 349(3):389-401.

View in: PubMed

People

Explore

Similar Concepts

Top Journals